Release details

2017-02-17 09:00 CET
  • Print
  • Share Share
fi en

Revenio Group Corporation: Notice pursuant to Chapter 9, Section 10 of the Securities Market Act

Revenio Group Corporation, Stock Exchange Release, February 17, 2017 at 10:00
 
NOTICE PURSUANT TO CHAPTER 9, SECTION 10 OF THE SECURITIES MARKET ACT
 
Revenio Group Corporation has today received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that Mr. Jyri Merivirta's share of the total number of shares and voting rights in Revenio Group Corporation has decreased to less than one fifth (1/5).
 
Mr. Jyri Merivirta now holds 250.00 shares in Revenio Group Corporation, which is 3.13 per cent of the company's shares and voting rights.
 
The total number of Revenio Group Corporation's shares recorded in the trade register is 7,979,406.
 
Revenio Group Corporation
Timo Hildén
President and CEO
 
For further information, please contact:

CEO&President Timo Hildén
Telephone: +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

 
DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
 
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on intraocular pressure measurement technology that has a strong patent. Revenio Group consists of, in addition to the parent company, Icare Finland Oy which focuses on intraocular pressure measurement technology and its fully owned subsidiary Icare USA Inc., research and development company Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up, and the global need to make cost savings through preventive health care.
 
Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer, and asthma, and the monitoring of these during the treatment process.
 
In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating margin for continuing operations standing at 30.1% from continuous operations. Revenio Group Corporation is listed on Nasdaq Helsinki.
HUG#2079629